Alexion’s Ondexxya approved for NHS Scotland to treat uncontrolled and life-threatening bleeds

pharmafile | September 9, 2020 | News story | Research and Development, Sales and Marketing Alexion, NHS, Ondexxya, Scotland, nhs scotland 

The Scottish Medicines Consortium (SMC) has given its recommendation to Alexion’s Ondexxya (andexanet alfa) to routine use on NHS Scotland for the treatment of life-threatening or uncontrolled bleeding in adult patients treated with the direct Factor Xa (FXa) inhibitors apixaban or rivaroxaban, it has emerged.

According to data harvested from two Phase 3 studies and a Phase 3b safety study, Ondexxya was shown to “markedly reduce” anti-factor Xa activity of apixaban and rivaroxaban, while 82% of evaluable patients receiving the drug saw their bleeding stop 12 hours after treatment compared to baseline.

The drug has been approved on an interim basis that is contingent upon further assessment of its efficacy.

“As the number of patients on direct Fxa inhibitors continues to increase, so does the need to ensure we can protect patients who may experience life-threatening or uncontrolled bleeds,” commented Professor Henry Watson, Consultant Haematologist at University of Aberdeen. “Andexanet alfa will give clinicians an approved therapy option and clinical strategy for the reversal of major bleeding in patients being treated with rivaroxaban and apixaban. This is a positive step forward for the safety of patients being treated with these important and widely used drugs.”

Ondexxya was originally developed by Portola Pharmaceuticals, which was acquired by Alexion in July this year. The drug secured approval from the European Commission in April 2019 and from the FDA in May 2018.

Matt Fellows

Related Content


UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs …

Report finds NHS may miss out on new drugs due to rising costs

Figures from a team at the University of York, the London School of Economics and …

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

Latest content